Nucleolin Overview
Molecule Name
Nucleolin
Synonyms
Nucleolin,NCL,Protein C23
Drug Development Progress
Drugs in Clinical Trials4
Approved Drugs1
Highest Development StageApproved
Target Synonym
NCL，Nucleolin，Protein C23，Nsr1，C23
Background
Nucleolin is the major nucleolar protein of growing eukaryotic cells. It is found associated with intranucleolar chromatin and pre-ribosomal particles. It induces chromatin decondensation by binding to histone H1. It is thought to play a role in pre-rRNA transcription and ribosome assembly. May play a role in the process of transcriptional elongation. Binds RNA oligonucleotides with 5'-UUAGGG-3' repeats more tightly than the telomeric single-stranded DNA 5'-TTAGGG-3' repeats.
Nucleolin Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| IPP-204106 | N6L; Nucant-6L; IPP-204106; IPP-204106N; poyplexed IPP-204106 | Phase 2 Clinical | Immupharma Plc | Neoplasms; Solid tumours | Details |
| AS-1411 | AGRO-100; GR-026-B; AS-1411; ACT-GRO-777 | Phase 2 Clinical | Antisoma, University Of Alabama At Birmingham, University Of Louisville | Neoplasms; Solid tumours | Details |
| Pegylated recombinant human endostatin (Tsinghua University) | M-2ES; CRB-0401 | Phase 1 Clinical | Beijing Proji Pharmaceutical Technology Co Ltd, Beijing Protgen Biotechnology Development Co Ltd, Tsinghua University | Carcinoma, Non-Small-Cell Lung; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| APTA-16 | APTA-16; SJP1604 | Phase 1 Clinical | Aptabio Therapeutics Inc | Leukemia, Myeloid, Acute; Liver Neoplasms; Myelodysplastic Syndromes | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant human endostatin (Simcere) | YH-16 | Approved | Jiangsu Simcere Pharmaceutical Co Ltd | Endostar, 恩度, Endu | Mainland China | Carcinoma, Non-Small-Cell Lung | Shandong Xiansheng Zaiming Biopharmaceutical Co Ltd | 2005-09-12 | Ascites; Brain metastases; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Head and Neck Neoplasms; Nasopharyngeal Carcinoma; Osteosarcoma; Pleural Effusion, Malignant | Details |